Aileron Therapeutics, Inc.
ALRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $54,041 | $50 | $44,928 | $45,542 |
| - Cash | $4,048 | $5,722 | $7,428 | $12,865 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $49,993 | -$5,672 | $37,500 | $32,677 |
| Revenue | $0 | $0 | $0 | $126 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $63 |
| % Margin | – | – | – | 50% |
| EBITDA | -$5,581 | -$6,871 | -$5,609 | -$40,985 |
| % Margin | – | – | – | -32,527.8% |
| Net Income | -$5,581 | -$6,822 | -$5,501 | -$40,981 |
| % Margin | – | – | – | -32,524.6% |
| EPS Diluted | -0.21 | -0.28 | -0.25 | -2.07 |
| % Growth | 25% | -12% | 87.9% | – |
| Operating Cash Flow | -$3,548 | -$6,418 | -$6,175 | -$4,812 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,548 | -$6,418 | -$6,175 | -$4,812 |